Shots:
- The P-III study involves assesing the safety, efficacy, immunogenicity & PK of BAT1806 vs Actemra/RoActemra (tocilizumab) in 621 patients with the mod. to sev. RA with inadequate response to methotrexate
- The study met its 1EPs that demonstrated equivalent efficacy and comparable safety profile to the Actemra/RoActemra. The 1EP of the study was ACR20
- Biogen has exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries excluding China (include Hong Kong, Macau, and Taiwan). In 2021, companies collaborated under which Bio-Thera will receive $30M payment following the achievement of P-III satisfactory results and is eligible for milestones along with royalties
Click here to read full press release/ article | Ref: Globe Newswire | Image: Stat News
The post Biogen and Bio-Thera Report Results of BAT1806 (biosimilar, tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis first appeared on PharmaShots.
